OMB KESIMPTA (OFATUMUMAB) 20 MG INJECTION
Live / Registered — Registered (as of 15 Aug 2023)
What this means for you
Registered since 15 Aug 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90533968
- Registration number
- 7139722
- Mark type
- Slogan / phrase
- Filed
- 18 Feb 2021
- Published for opposition
- 19 Oct 2021
- Registered
- 15 Aug 2023
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 044 — Medical, beauty and agricultural services: Providing health information about pharmaceuticals containing monoclonal antibodies
Owner
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
Prior registrations
Prosecution history
- 15 Aug 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 15 Aug 2023 — REGISTERED-PRINCIPAL REGISTER
- 13 Jul 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 12 Jul 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 12 Jul 2023 — EXAMINER'S AMENDMENT ENTERED
- 12 Jul 2023 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 12 Jul 2023 — EXAMINERS AMENDMENT E-MAILED
- 12 Jul 2023 — SU-EXAMINER'S AMENDMENT WRITTEN
- 07 Jul 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Jul 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 28 Jun 2023 — USE AMENDMENT FILED
- 06 Jul 2023 — SOU EXTENSION 4 GRANTED
- 28 Jun 2023 — SOU EXTENSION 4 FILED
- 06 Jul 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 28 Jun 2023 — SOU TEAS EXTENSION RECEIVED